We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » VALID Act Remains Priority for FDA in 2023, Says FDA Deputy Commissioner
VALID Act Remains Priority for FDA in 2023, Says FDA Deputy Commissioner
The overhauling of the FDA’s oversight of in vitro diagnostics will see significant movement in 2023, according to Andi Fristedt, the agency’s deputy commissioner for policy, legislation and international affairs.